Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Joachim Stoltenborg Granhøj"'
Autor:
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Özcan Met
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/ef1231a8b35045258c3dac4c45de3bd2
Autor:
Marco Donia, Marie Christine Wulff Westergaard, Sine Reker Hadrup, Kalijn Bol, Inge Marie Svane, Arianna Draghi, Anders Jespersen, Sofie Kirial Mørk, Christina Westmose Yde, Torben Lorentzen, Mohammad Kadivar, Daniela Kleine-Kohlbrecher, Benedetta Albieri, Joachim Stoltenborg Granhøj, Signe Koggersbøl Skadborg, Annie Borch, Nadia Viborg Petersen, Nikolas Thuesen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Rebecca Bach Dohn, Nis Noergaard, Anders Bundgaard Soerensen, Dennis Christensen, Jens Kringelum
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Neoantigens can serve as targets for T cell-mediated antitumor immunity via personalized neopeptide vaccines. Interim data from our clinical study NCT03715985 showed that the personalized peptide-based neoantigen vaccine EVX-01, formulated
Externí odkaz:
https://doaj.org/article/ba4e7a8820d44fe594ecfd552cb83643
Autor:
Marco Donia, Troels Holz Borch, Inge Marie Svane, Víctor Albarrán Fernández, Pablo Ballestín Martínez, Joachim Stoltenborg Granhøj
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding
Externí odkaz:
https://doaj.org/article/23edc9b1559e4db384fed3e30601a05e
Autor:
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhøj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Özcan Met
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) are the two most effective immunotherapies for the treatment of metastatic melanoma. While CPI has been the dominating therap
Externí odkaz:
https://doaj.org/article/7afe16c86d48470cacf63c8ae355b95e
Autor:
Sofie Kirial Mørk, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhøj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmström, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Nørgaard, Lars Vibe Andreasen, Grith Krøyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per thor Straten, Mads Hald Andersen, Inge Marie Svane
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe B-cell lymphoma-extra-large (Bcl-XL) protein plays an important role in cancer cells’ resistance to apoptosis. Pre-clinical studies have shown that vaccination with Bcl-XL-derived peptides can induce tumor-specific T cell responses th
Externí odkaz:
https://doaj.org/article/9c685780fcea4f8588fac16748a76464
Autor:
Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen
Publikováno v:
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125
Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr
Autor:
Joachim Stoltenborg Granhøj, Agnete Witness Præst Jensen, Mario Presti, Özcan Met, Inge Marie Svane, Marco Donia
Publikováno v:
Expert Opinion on Biological Therapy. 22:627-641
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a highly personalized type of cancer immunotherapy. TIL-based ACT exploits naturally occurring TILs, derived from the patients' tumor. This treatment has shown consistent clini